Sep. 16, 2009 (Filing Services Canada) -- Orbus Pharma Inc. (ORB - TSX), announces an agreement in principle has been reached on the terms of a settlement related to ownership of real property in Alberta. The agreement stipulates that Orbus will retain unrestricted title to a portion of the land in question.

Orbus intends to list the property for sale at the earliest possible date. Proceeds from the sale (net of legal and sale costs) are expected in the range of $1.1 to $1.4 million.

Orbus Pharma Inc., headquartered in Markham, Ontario and listed on the Toronto Stock Exchange under the symbol ORB, is pursuing an integrated global strategy of: (1) generic drug development, using proprietary delivery systems for certain products; (2) product out-licensing; and (3) pharmaceutical manufacturing. For more information, please visit www.orbus.ca.
Forward-looking statements

Certain statements in this disclosure are ?forward-looking statements?, which reflect management?s expectations regarding the Company?s future growth, results of operations, performance and business prospects and opportunities. Such forward-looking statements reflect management?s current beliefs and are based on information currently available to management. Many factors could cause results to differ materially from the results discussed in the forward-looking statements, including risks related to dependence on key suppliers, economic conditions, competition, regulatory change, foreign exchange rates, and interest rates, among others. Although the forward-looking statements are based on what management believes to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward-looking statements.
Please contact the following Orbus officers for further information:

Greg W. Muir
Interim President and C.E.O.
(905) 943-9444 ext 222
Source: Orbus Pharma Inc. (TSX: ORB) http://www.orbus.ca
Maximum News Dissemination by Filing Services Canada Inc. *
www.usetdas.com